Androgen receptor expression and outcomes in early breast cancer: A systematic review and meta-analysis

Journal of the National Cancer Institute

Volumn 106, Issue 1, 2014, Pages

  Vera Badillo, Francisco E ^a   Templeton, Arnoud J ^a   De Gouveia, Paulo ^a   Diaz Padilla, Ivan ^a   Bedard, Philippe L ^a   Al Mubarak, Mustafa ^a   Seruga, Bostjan ^b   Tannock, Ian F ^a   Ocana, Alberto ^a,c   Amir, Eitan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; AR PROTEIN, HUMAN; KI 67 ANTIGEN; TUMOR MARKER;

BREAST CANCER; CANCER SURVIVAL; DATA BASE; DISEASE FREE SURVIVAL; EARLY CANCER; EMBASE; GENE EXPRESSION; HUMAN; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER GRADING; CANCER STAGING; EARLY DIAGNOSIS; FACTUAL DATABASE; FEMALE; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; RISK; TUMOR INVASION;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ODDS RATIO; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84892632994     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt319     Document Type: Review

References (54)

1. Samaan NA, Buzdar AU, Aldinger KA, et al. Estrogen receptor: a prognostic factor in breast cancer. Cancer. 1981;47(3):554-560.
2. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
3. Schippinger W, Regitnig P, Dandachi N, et al. Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch. 2006;449(1):24-30.
4. Hu R, Dawood S, Holmes MD, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011;17(7):1867-1874.
5. Gucalp A, Tolaney S, Isakoff S, et al. Targeting the androgen receptor (AR) in women with AR+ ER-/PR-metastatic breast cancer (MBC). J Clin Oncol. 2012;30(Suppl):abstract 1006.
6. Kennedy BJ. Fluoxymesterone therapy in advanced breast cancer. N Engl J Med. 1958;259(14):673-675.
7. Stoll BA. Fluoxymesterone (halotestin) in advanced breast carcinoma. Med J Aust. 1959;46(3):70-74.
8. Beckett VL, Brennan MJ. Treatment of advanced breast cancer with fluoxymesterone (halotestin). Surg Gynecol Obstet. 1959;109(2):235-239.
9. Lowe R, De Lorimier AA Jr, Gordan GS, et al. Antitumor efficacy of fluoxymesterone. Use in advanced breast cancer. Arch Intern Med. 1961;107:241-244.
10. Ingle JN, Suman VJ, Mailliard JA, et al. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat. 2006;98(2):217-222.
11. Ingle JN, Twito DI, Schaid DJ, et al. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. J Clin Oncol. 1988;6(5):825-831.
12. Hackenberg R, Schulz KD. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen-and androgen-like steroids. J Steroid Biochem Mol Biol. 1996;56(1-6):113-117.
13. Peters AA, Buchanan G, Ricciardelli C, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009;69(15):6131-6140.
14. Cops EJ, Bianco-Miotto T, Moore NL, et al. Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. J Steroid Biochem Mol Biol. 2008;110(3-5):236-243.
15. Panet-Raymond V, Gottlieb B, Beitel LK, et al. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol. 2000;167(1-2):139-150.
16. Robinson JL, Macarthur S, Ross-Innes CS, et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011;30(15):3019-3027.
17. Wong YC, Xie B. The role of androgens in mammary carcinogenesis. Ital J Anat Embryol. 2001;106(2 Suppl 1):111-125.
18. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24(29):4660-4671.
19. Mackay A, Weigelt B, Grigoriadis A, et al. Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst. 2011;103(8):662-673.
20. Michiels S, Piedbois P, Burdett S, et al. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care. 2005;21(1):119-125.
21. Deeks JJ, Higgins JPT, Altman DG. Analysing and presenting results. In: Higgins JPT, Green S, ed. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Chichester, UK: John Wiley & Sons; 2006.
22. Agrawal AK, Jelen M, Grzebieniak Z, et al. Androgen receptors as a prognostic and predictive factor in breast cancer. Folia Histochem Cytobiol. 2008;46(3):269-276.
23. Honma N, Horii R, Iwase T, et al. Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy. Breast Cancer. 2012 Feb 4. [Epub ahead of print].
24. Park S, Koo J, Park HS, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;21(3):488-492.
25. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20(17):3628-3636.
26. Witzel I, Graeser M, Karn T, et al. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. J Cancer Res Clin Oncol. 2013;139(5):809-816.
27. Niemeier LA, Dabbs DJ, Beriwal S, et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;23(2):205-212.
28. Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia. 2008;10(6):542-548.
29. Agrawal A, Robertson JF, Cheung KL. "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer. World J Surg Oncol. 2006 Jul 5;4:40.
30. Raam S, Robert N, Pappas CA, et al. Defective estrogen receptors in human mammary cancers: their significance in defining hormone dependence. J Natl Cancer Inst. 1988;80(10):756-761.
31. McGuire WL, Chamness GC, Fuqua SA. Abnormal estrogen receptor in clinical breast cancer. J Steroid Biochem Mol Biol. 1992;43(1-3):243-247.
32. Faridi J, Wang L, Endemann G, et al. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res. 2003;9(8):2933-2939.
33. Hui R, Finney GL, Carroll JS, et al. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res. 2002;62(23):6916-6923.
34. Miller TW, Perez-Torres M, Narasanna A, et al. Loss of phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulinlike growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res. 2009;69(10):4192-4201.
35. Prall OW, Rogan EM, Musgrove EA, et al. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol. 1998;18(8):4499-4508.
36. De Amicis F, Thirugnansampanthan J, Cui Y, et al. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010;121(1):1-11.
37. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.
38. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
39. Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer. http://www.clinicaltrials.gov/ct2/show/NCT00 755885?term=abiraterone+breast+cancer&rank=2. Accessed October 11, 2013.
40. A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy. http://www. clinicaltrials.gov/ct2/show/study/NCT01381874?term=abiraterone+breas t+cancer&rank=1&show-locs=Y#locn. Accessed October 11, 2013.
41. Carreno G, Del Casar JM, Corte MD, et al. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics. Breast Cancer Res Treat. 2007;102(1):61-73.
42. Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer. 1996;32A(9):1560- 1565.
43. Yu Q, Niu Y, Liu N, et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol. 2011;22(6):1288-1294.
44. Castellano I, Allia E, Accortanzo V, et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. 2010;124(3):607-617.
45. Gonzalez LO, Corte MD, Vazquez J, et al. Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer. 2008 May 28;8:149.
46. Loibl S, Muller BM, von Minckwitz G, et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011;130(2):477-487.
47. Luo X, Shi YX, Li ZM, et al. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer. 2010;29(6):585-590.
48. Micello D, Marando A, Sahnane N, et al. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Arch. 2010;457(4):467-476.
49. Peters KM, Edwards SL, Nair SS, et al. Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events. BMC Cancer. 2012 Apr 2;12:132.
50. Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003;120(5):725-731.
51. Bryan RM, Mercer RJ, Bennett RC, et al. Androgen receptors in breast cancer. Cancer. 1984;54(11):2436-2440.
52. Langer M, Kubista E, Schemper M, et al. Androgen receptors, serum androgen levels and survival of breast cancer patients. Arch Gynecol Obstet. 1990;247(4):203-209.
53. Collet K, Maehle BO, Skaerven R, Aas T. Prognostic role of oestrogen, progesterone and androgen receptor in relation to patient age in patients with breast cancer. Breast. 1996;5(3):123-126.
54. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15(7):2472-2478.